Cooperate with Guangdong Zhongsheng Pharmaceutical Co., Ltd. to study the fingerprint of Compound Xueshuantong Capsule, which has reached the international advanced level through the identification of scientific and technological achievements; And declared the national invention patent "Construction method of HPLC fingerprint of compound Xueshuantong preparation and its standard fingerprint". The fingerprint quality control technology of Shengpai compound Xueshuantong preparation successfully solved the core problem of drug standardization, ensured the safety and effectiveness of Shengpai compound Xueshuantong capsule in Guangdong famous brand products, and will also play an important social role in preventing counterfeiting, distinguishing advantages and disadvantages, improving quality standards, further enhancing corporate brands and ensuring public medication safety.
The fingerprint quality control technology of "Kouyanqing Granule" was established for Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., and two invention patents were applied, which provided technical guarantee for the quality control of this product.
At present, it has undertaken the national "Eleventh Five-Year" science and technology support project "Study on the new mode of quality control of spectral efficacy of traditional Chinese medicine with Lingnan characteristics", and established a new mode of quality control of spectral efficacy of traditional Chinese medicine with Lingnan characteristics as the research carrier, so as to make the quality control method of traditional Chinese medicine in line with international standards; Improve the quality control level of traditional Chinese medicine as a whole, and its core technology has independent intellectual property rights completely.
In recent years, through the extraction and separation of effective parts and related research on pharmacy, pharmacodynamics, pharmacology and toxicology, the biological activity of traditional Chinese medicine with Lingnan characteristics was screened, and innovative drugs with independent intellectual property rights were developed. Three clinical approvals for new drugs have been obtained, all of which have independent intellectual property rights. Another three innovative Chinese medicine varieties (Class I and Class V new Chinese medicine) are about to complete preclinical research.
In recent years, 28 national invention patents have been declared and granted 15. A number of patents have realized technology transfer and industrialization.
In 2008, she was awarded the fourth "New Century Female Inventor" Excellence Award by China National Intellectual Property Administration, All-China Women's Federation and China Invention Association.
20 10 Professor Su Weiwei was awarded the "Fifth Invention and Entrepreneurship Award" by China Invention Association.